Bridging decision analytic modelling with a cross-sectional study. Application to Parkinson's disease

Area of Science:

• Health Economics
• Pharmacoeconomics
• Clinical Trial Design

Background:

• Prospective studies are ideal for drug outcome and cost assessment but often infeasible.
• Decision analytic models can supplement missing data but face bias concerns with Delphi panels.
• Accurate economic data is crucial for pharmaceutical reimbursement decisions.

Purpose of the Study:

• To present a novel hybrid study design integrating cross-sectional data with decision analytic modeling.
• To address limitations of prospective studies and Delphi panels in economic evaluations.
• To enhance the external validity and logistical efficiency of modeling studies.

Main Methods:

• Utilized cross-sectional study data to derive costs and utilities for Markov health states.
• Combined literature/clinical trial probabilities with cross-sectional cost and utility data.
• Developed a hybrid design as a blend of naturalistic prospective and modeling approaches.
• Applied the hybrid design using a Markov model for Parkinson's disease.

Main Results:

• The hybrid design maximizes strengths and minimizes weaknesses of prospective and modeling studies.
• It offers increased external validity compared to traditional modeling approaches.
• Logistical advantages include a shorter study duration than prospective naturalistic studies.

Conclusions:

• The proposed hybrid design offers a robust alternative for generating reliable health economic data.
• It effectively bridges evidence from clinical research with real-world cost and utility information.
• This approach enhances the accuracy and feasibility of economic evaluations for pharmaceutical reimbursement.